17.10

3.28% -0.58

Pre-market: 20.50 3.40 +19.88%

Janux Therapeutics Inc (JANX)

Overview News Price History Option Chain Financials Discussions Forecast

Janux Therapeutics Inc stock is traded at $17.10, with a volume of 791.39K. It is down -3.28% in the last 24 hours and up +3.51% over the past month. Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Previous Close:

$17.68

Open:

$17.92

24h Volume:

791.39K

Relative Volume:

0.79

Market Cap:

$1.05B

Revenue:

$13.73M

Net Income/Loss:

$-114.48M

P/E Ratio:

-9.2844

EPS:

-1.8418

Net Cash Flow:

$-78.49M

1W Performance:

-15.51%

1M Performance:

+3.51%

6M Performance:

+21.45%

1Y Performance:

-31.93%

1-Day Range:

$17.05

$17.94

1-Week Range:

$17.05

$20.25

52-Week Range:

$12.12

$35.34

Janux Therapeutics Inc Stock (JANX) Company Profile

Name

Janux Therapeutics Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(858) 751-4493

Address

10955 VISTA SORRENTO PARKWAY, SAN DIEGO

Employee

108

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

JANX's Discussions on Twitter

Compare JANX vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JANX Janux Therapeutics Inc	17.10	1.05B	13.73M	-114.48M	-78.49M	-1.8418
VRTX Vertex Pharmaceuticals Inc	515.44	130.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	781.49	80.46B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	984.39	61.58B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	143.97	57.48B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	203.77	43.68B	742.00K	-1.37B	-1.07B	-7.0731

Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-24-26	Upgrade	Wolfe Research	Peer Perform → Outperform
Apr-20-26	Downgrade	Barclays	Overweight → Underweight
Apr-15-26	Downgrade	UBS	Buy → Neutral
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-17-25	Initiated	Barclays	Overweight
Sep-10-25	Initiated	Stifel	Buy
Sep-10-25	Initiated	Truist	Buy
Sep-04-25	Initiated	Guggenheim	Buy
Aug-19-25	Initiated	Piper Sandler	Overweight
Jul-11-25	Initiated	Raymond James	Outperform
Dec-03-24	Reiterated	BTIG Research	Buy
Dec-03-24	Reiterated	H.C. Wainwright	Buy
Nov-22-24	Initiated	Leerink Partners	Outperform
Oct-24-24	Initiated	UBS	Buy
Sep-06-24	Initiated	Stifel	Buy
May-30-24	Initiated	Scotiabank	Sector Perform
Mar-21-24	Initiated	BTIG Research	Buy
Mar-20-24	Initiated	Cantor Fitzgerald	Overweight
Apr-06-23	Initiated	Wedbush	Outperform
Nov-14-22	Initiated	William Blair	Outperform

View All

Janux Therapeutics Inc Stock (JANX) Latest News

Sep 11, 2026

Price-Driven Insight from (JANX) for Rule-Based Strategy - Stock Traders Daily

Sep 11, 2026

Sep 03, 2026

Janux’s JANX014 Prostate Cancer Trial Advances, Keeping Early-Stage Upside in Play - TipRanks

Sep 03, 2026

Sep 01, 2026

Understanding the Setup: (JANX) and Scalable Risk - Stock Traders Daily

Sep 01, 2026

Aug 26, 2026

How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44% - qz.com

Aug 26, 2026

Aug 24, 2026

Wolfe Research Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $23 - Moomoo

Aug 24, 2026

Wolfe Research upgrades Janux stock rating on autoimmune data By Investing.com - Investing.com Canada

Aug 24, 2026

Wolfe Research upgrades Janux stock rating on autoimmune data - investing.com

Aug 24, 2026

Aug 21, 2026

JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know - TradingView

Aug 21, 2026

Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile? - Sahm

Aug 21, 2026

Aug 20, 2026

A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $60 - Moomoo

Aug 20, 2026

Janux (JANX) Latest Quarter: EPS Lands Above Forecast; Market Reaction: Shares Finish 3.30% Higher on the DayEstimate Revision Count - vinanet.vn

Aug 20, 2026

Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Aug 20, 2026

Aug 15, 2026

Dimensional Fund Advisors LP Has $1.34 Million Stake in Janux Therapeutics, Inc. $JANX - MarketBeat

Aug 15, 2026

Aug 14, 2026

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA) - The Globe and Mail

Aug 14, 2026

Point72 reports 3.3% beneficial stake in Janux Therapeutics (JANX) via managed fund - Stock Titan

Aug 14, 2026

Aug 13, 2026

Janus Henderson Group (JANX) reports 172,229 Janux Therapeutics shares under management - Stock Titan

Aug 13, 2026

JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits

Aug 13, 2026

William Blair Maintains Janux Therapeutics(JANX.US) With Buy Rating - moomoo.com

Aug 13, 2026

Aug 12, 2026

Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $35 - Moomoo

Aug 12, 2026

Janux Therapeutics (JANX) Gains 0.91% as Shares Firmly Hold Above $15.84 SupportHigh Conviction Picks - Vinanet

Aug 12, 2026

Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile - Yahoo Finance

Aug 11, 2026

Janus Living Prices Share Offering - marketscreener.com

Aug 11, 2026

Aug 10, 2026